What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective
Value in Health · 2026
DOI: 10.1016/j.jval.2025.09.003 ↗Kurz gefasst
Editorial in der Zeitschrift Value in Health, 2026. Verfasst von James Koh und 1 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health and Care Excellence, Manchester, England, UK; Centre for Health Economics, University of York, York, England, UK. Elect…. Hauptthemen laut MEDLINE: Practice Guidelines as Topic, Technology Assessment, Biomedical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: National Institute of Clean-and-Low-Carbon Energy.
Abstract (Originalsprache)
The perspective of an economic evaluation defines what types of benefit and cost are counted when assessing the value for money of a health intervention. The health sector perspective counts health outcomes and health system costs, whereas a societal perspective includes effects relevant to other forms of public expenditure, such as benefits to educational attainment or economic productivity. This article describes how the National Institute for Health and Care Excellence evaluated the arguments for and against the adoption of a societal perspective and articulates the rationale for its decision to retain a health sector perspective in its value-for-money assessments but with flexibility to consider wider societal effects when they are especially relevant to the value of a health intervention. The appropriate perspective to take is dependent upon the objective function of the payer. Under specific conditions, a publicly funded payer could optimize decision making across public sector budgets by adopting a full societal perspective. However, there are a range of ethical, practical, and methodological problems that arise when trying to implement a societal perspective. These include a lack of evidence on the opportunity cost of nonhealth outcomes to calculate net effects, no robust methodology to inform trade-offs between health and nonhealth sector outcomes, and the discriminatory consequences of counting productivity effects. We discuss how these considerations are balanced against the need to consider the value of nonhealth effects during the technology evaluation and guideline production processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Institute for Health and Care Excellence, Manchester, England, UK; Centre for Health Economics, University of York, York, England, UK. Electronic address: james.koh@nice.org.uk.
- National Institute for Health and Care Excellence, London, England, UK; Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, England, UK. Electronic address: koonal.shah@nice.org.uk.
Förderung
- National Institute of Clean-and-Low-Carbon Energy
Zitieren
APA
Koh, J., & Shah, K. (2026). What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective. Value in Health. https://doi.org/10.1016/j.jval.2025.09.003
Vancouver
Koh J, Shah K. What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective. Value in Health. 2026. doi:10.1016/j.jval.2025.09.003
BibTeX
@article{Koh2026,
author = {Koh, James and Shah, Koonal},
title = {What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective},
journal = {Value in Health},
year = {2026},
doi = {10.1016/j.jval.2025.09.003}
}
EUVIMED